US7846445B2
(en)
*
|
2005-09-27 |
2010-12-07 |
Amunix Operating, Inc. |
Methods for production of unstructured recombinant polymers and uses thereof
|
US7855279B2
(en)
|
2005-09-27 |
2010-12-21 |
Amunix Operating, Inc. |
Unstructured recombinant polymers and uses thereof
|
US20130172274A1
(en)
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
WO2007073486A2
(en)
|
2005-12-20 |
2007-06-28 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
CA2682147C
(en)
|
2007-03-30 |
2017-08-08 |
Ambrx, Inc. |
Modified fgf-21 polypeptides and their uses
|
KR101631323B1
(ko)
|
2007-06-21 |
2016-06-17 |
엑스엘-프로테인 게엠베하 |
증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질
|
WO2009023270A2
(en)
|
2007-08-15 |
2009-02-19 |
Amunix, Inc. |
Compositions and methods for modifying properties of biologically active polypeptides
|
WO2009140599A1
(en)
|
2008-05-15 |
2009-11-19 |
Transmolecular, Inc. |
Treatment of metastatic tumors
|
EP4074327A1
(en)
|
2008-06-27 |
2022-10-19 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
US8680050B2
(en)
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
US8703717B2
(en)
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
CN116925238A
(zh)
|
2009-02-03 |
2023-10-24 |
阿穆尼克斯制药公司 |
延伸重组多肽和包含该延伸重组多肽的组合物
|
DK2440228T3
(da)
|
2009-06-08 |
2018-12-17 |
Amunix Operating Inc |
Glucoseregulerende polypeptider og fremgangsmåder til fremstilling og anvendelse deraf
|
MX354555B
(es)
*
|
2009-06-08 |
2018-03-09 |
Amunix Operating Inc |
Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso.
|
US9849188B2
(en)
|
2009-06-08 |
2017-12-26 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
CA2772051C
(en)
*
|
2009-08-24 |
2020-08-18 |
Amunix Operating Inc. |
Coagulation factor ix compositions and methods of making and using same
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
RS56231B1
(sr)
|
2010-02-04 |
2017-11-30 |
Morphotek Inc |
Polipeptidi i konjugati hlorotoksina i njihove upotrebe
|
EP2552967A4
(en)
*
|
2010-04-02 |
2014-10-08 |
Amunix Operating Inc |
BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE
|
WO2011123830A2
(en)
|
2010-04-02 |
2011-10-06 |
Amunix Operating Inc. |
Alpha 1-antitrypsin compositions and methods of making and using same
|
TWI510246B
(zh)
|
2010-04-30 |
2015-12-01 |
Molecular Partners Ag |
抑制vegf-a受體交互作用的經修飾結合性蛋白質
|
EP3165533B1
(en)
|
2010-05-11 |
2020-04-08 |
Fred Hutchinson Cancer Research Center |
Chlorotoxin variants, conjugates and methods for their use
|
US9238080B2
(en)
|
2010-05-21 |
2016-01-19 |
Merrimack Pharmaceuticals, Inc. |
Bi-specific fusion proteins
|
CA2794614C
(en)
|
2010-05-21 |
2020-12-15 |
Xl-Protein Gmbh |
Biosynthetic proline/alanine random coil polypeptides and their uses
|
JP5709985B2
(ja)
|
2010-06-18 |
2015-04-30 |
シーバーサイエンス ゲーエムベーハー |
生体バリアを安定化させる活性剤としてのペプチド
|
PL3470421T3
(pl)
|
2010-07-29 |
2023-10-23 |
Buzzard Pharmaceuticals AB |
Chimeryczne antagonisty receptora il-1 typu i
|
EP3514169B1
(en)
|
2010-11-26 |
2024-03-06 |
Molecular Partners AG |
Designed repeat proteins binding to serum albumin
|
IL210093A0
(en)
|
2010-12-19 |
2011-06-30 |
David Helman |
Membrane bound reporter molecules and their use in cell sorting
|
WO2012103240A2
(en)
|
2011-01-25 |
2012-08-02 |
Eleven Biotherapeutics, Inc. |
Receptor binding agents
|
PT2717898T
(pt)
|
2011-06-10 |
2019-05-20 |
Bioverativ Therapeutics Inc |
Compostos pró-coagulantes e processos para a sua utilização
|
TWI764092B
(zh)
|
2011-07-08 |
2022-05-11 |
美商百歐維拉提夫治療公司 |
因子viii嵌合及雜交多肽,及其使用方法
|
WO2013016454A1
(en)
|
2011-07-25 |
2013-01-31 |
Biogen Idec Hemophilia Inc. |
Assays to monitor bleeding disorders
|
RU2014107743A
(ru)
|
2011-07-29 |
2015-09-10 |
Илэвэн Байотерапьютикс, Инк. |
Очищенные белки
|
AU2012296951B2
(en)
*
|
2011-08-12 |
2016-09-15 |
Ascendis Pharma A/S |
Protein carrier-linked prodrugs
|
BR112014003225A2
(pt)
|
2011-08-12 |
2017-03-01 |
Ascendis Pharma As |
profármacos de treprostinil ligados a veículo
|
SI2804623T1
(sl)
|
2012-01-12 |
2020-02-28 |
Bioverativ Therapeutics Inc. |
Himerni polipeptidi faktorja VIII in njihove uporabe
|
US20130210747A1
(en)
|
2012-02-13 |
2013-08-15 |
University Of Southern California |
Methods and Therapeutics Comprising Ligand-Targeted ELPs
|
ES2935489T3
(es)
|
2012-02-15 |
2023-03-07 |
Bioverativ Therapeutics Inc |
Composiciones de factor VIII y métodos de preparación y uso de las mismas
|
LT2822577T
(lt)
|
2012-02-15 |
2019-03-25 |
Bioverativ Therapeutics Inc. |
Rekombinantiniai faktoriaus viii baltymai
|
CA3179537A1
(en)
|
2012-02-27 |
2013-09-06 |
Amunix Pharmaceuticals, Inc. |
Xten conjugate compositions and methods of making same
|
ES2753135T3
(es)
|
2012-05-07 |
2020-04-07 |
Allergan Inc |
Método de tratamiento de DMAE en pacientes resistentes a terapia anti-VEGF
|
EP3693000B1
(en)
|
2012-06-08 |
2022-03-02 |
Bioverativ Therapeutics Inc. |
Procoagulant compounds
|
WO2013185114A2
(en)
|
2012-06-08 |
2013-12-12 |
Biogen Idec Ma Inc. |
Chimeric clotting factors
|
MX2014015825A
(es)
|
2012-06-28 |
2015-08-10 |
Molecular Partners Ag |
Proteinas de repeticion de anquirina diseñadas que se unen al factor de crecimiento derivado de plaquetas.
|
US10023628B2
(en)
|
2012-07-06 |
2018-07-17 |
Bioverativ Therapeutics Inc. |
Cell line expressing single chain factor VIII polypeptides and uses thereof
|
PT2882450T
(pt)
|
2012-07-11 |
2020-02-19 |
Bioverativ Therapeutics Inc |
Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo
|
WO2014026054A2
(en)
|
2012-08-10 |
2014-02-13 |
University Of Southern California |
CD20 scFv-ELPs METHODS AND THERAPEUTICS
|
US20140092376A1
(en)
*
|
2012-10-01 |
2014-04-03 |
Momentive Performance Materials, Inc. |
Container and method for in-line analysis of protein compositions
|
WO2014063108A1
(en)
|
2012-10-18 |
2014-04-24 |
Biogen Idec Ma Inc. |
Methods of using a fixed dose of a clotting factor
|
EP2914293A4
(en)
|
2012-10-30 |
2016-04-20 |
Biogen Ma Inc |
METHOD OF USE OF FVIII POLYPEPTIDE
|
WO2014081849A1
(en)
|
2012-11-20 |
2014-05-30 |
Phasebio Pharmaceuticals, Inc. |
Formulations of active agents for sustained release
|
EP2738180A1
(en)
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
US20150316536A1
(en)
|
2012-12-10 |
2015-11-05 |
Fred Hutchinson Cancer Research Center |
Methods for screening
|
TWI674270B
(zh)
|
2012-12-11 |
2019-10-11 |
英商梅迪繆思有限公司 |
用於治療肥胖之升糖素與glp-1共促效劑
|
US10370431B2
(en)
|
2013-02-15 |
2019-08-06 |
Bioverativ Therapeutics Inc. |
Optimized factor VIII gene
|
EP2968468B1
(en)
|
2013-03-13 |
2021-07-14 |
Buzzard Pharmaceuticals AB |
Chimeric cytokine formulations for ocular delivery
|
AU2014230472A1
(en)
|
2013-03-14 |
2015-10-01 |
Medimmune Limited |
Pegylated glucagon and GLP-1 co-agonists for the treatment of obesity
|
SG11201505926VA
(en)
|
2013-03-15 |
2015-09-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
TWI690325B
(zh)
|
2013-03-15 |
2020-04-11 |
美商百歐維拉提夫治療公司 |
因子viii多肽調配物
|
WO2015022326A1
(en)
|
2013-08-12 |
2015-02-19 |
Xiber Science Gmbh |
Peptides as active agents for treating primary graft dysfunction
|
EP3033098B1
(en)
|
2013-08-14 |
2022-06-22 |
Bioverativ Therapeutics Inc. |
Recombinant factor viii proteins
|
US10548953B2
(en)
|
2013-08-14 |
2020-02-04 |
Bioverativ Therapeutics Inc. |
Factor VIII-XTEN fusions and uses thereof
|
DK3041513T3
(da)
|
2013-09-08 |
2020-10-26 |
Kodiak Sciences Inc |
Zwitterioniske faktor viii-polymerkonjugater
|
US11559580B1
(en)
|
2013-09-17 |
2023-01-24 |
Blaze Bioscience, Inc. |
Tissue-homing peptide conjugates and methods of use thereof
|
US10611794B2
(en)
|
2013-09-25 |
2020-04-07 |
Bioverativ Therapeutics Inc. |
On-column viral inactivation methods
|
EP3065761B1
(en)
|
2013-11-05 |
2020-01-08 |
Allergan, Inc. |
Method of treating conditions of the eye with an anti-vegf darpin
|
EP3065769A4
(en)
|
2013-11-08 |
2017-05-31 |
Biogen MA Inc. |
Procoagulant fusion compound
|
US20160296600A1
(en)
|
2013-11-11 |
2016-10-13 |
Ascendis Pharma Relaxin Division A/S |
Relaxin Prodrugs
|
DE102013113156A1
(de)
|
2013-11-28 |
2015-05-28 |
Freie Universität Berlin |
Verbindung und Verfahren zur selektiven Radiomarkierung von Polypeptiden mittels Festphasensynthese
|
EP4332839A2
(en)
|
2013-12-06 |
2024-03-06 |
Bioverativ Therapeutics Inc. |
Population pharmacokinetics tools and uses thereof
|
EP3102224B1
(en)
|
2013-12-20 |
2019-02-20 |
NephroGenesis, LLC. |
Apparatuses for kidney dialysis and lipocalin protein for use in the prevention or treatment of uremia by dialysis
|
IL246476B
(en)
|
2014-01-10 |
2022-06-01 |
Biogen Ma Inc |
Factor viii chimeric proteins and their uses
|
WO2015132004A1
(en)
|
2014-03-05 |
2015-09-11 |
Merz Pharma Gmbh & Co. Kgaa |
Novel recombinant clostridial neurotoxins with increased duration of effect
|
US10772942B2
(en)
|
2014-03-24 |
2020-09-15 |
Bioverativ Therapeutics Inc. |
Lyophilized factor IX formulations
|
EP2937096B1
(en)
|
2014-04-23 |
2019-08-21 |
Julius-Maximilians-Universität Würzburg |
Peptides derived from RS1 which down-regulate glucose absorption after a glucose rich meal and increase insulin sensitivity
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
WO2016004113A1
(en)
|
2014-06-30 |
2016-01-07 |
Biogen Ma Inc. |
Optimized factor ix gene
|
US9616114B1
(en)
|
2014-09-18 |
2017-04-11 |
David Gordon Bermudes |
Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
|
EA201790699A1
(ru)
|
2014-09-26 |
2017-10-31 |
Байер Фарма Акциенгезельшафт |
Стабилизированные производные адреномедуллина и их применение
|
WO2016051340A1
(en)
|
2014-09-30 |
2016-04-07 |
Consiglio Nazionale Delle Ricerche |
A fusion protein, a nanoparticle composed by a plurality of monomers of said fusion protein, and uses thereof
|
ES2753391T3
(es)
|
2014-10-14 |
2020-04-08 |
Halozyme Inc |
Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
|
KR102210104B1
(ko)
|
2014-10-17 |
2021-02-01 |
코디악 사이언시스 인코포레이티드 |
부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
LT3412302T
(lt)
|
2014-10-24 |
2021-07-26 |
Bristol-Myers Squibb Company |
Modifikuoti fgf-21 polipeptidai ir jų panaudojimai
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
DK3220892T3
(da)
|
2014-11-21 |
2021-11-08 |
Ascendis Pharma Endocrinology Div A/S |
Langtidsvirkende væksthormondoseringsformer
|
CA2967394A1
(en)
|
2014-11-21 |
2016-05-26 |
Phasebio Pharmaceuticals, Inc. |
Elp fusion proteins for controlled and sustained release
|
WO2016094627A1
(en)
|
2014-12-10 |
2016-06-16 |
S-Aima Holding Company, Llc |
Generation of hemoglobin-based oxygen carriers using elastin-like polypeptides
|
AU2016219513B2
(en)
|
2015-02-09 |
2021-09-30 |
Immunoforge Co., Ltd. |
Methods and compositions for treating muscle disease and disorders
|
US10478394B2
(en)
|
2015-03-11 |
2019-11-19 |
Wayne State University |
Compositions and methods to promote wound healing
|
KR102427117B1
(ko)
|
2015-04-02 |
2022-07-29 |
몰리큘라 파트너스 아게 |
혈청 알부민에 대한 결합 특이성을 갖는 설계된 안키린 반복 도메인
|
TWI726889B
(zh)
|
2015-06-10 |
2021-05-11 |
英商梅迪繆思有限公司 |
蛋白酶抗性之脂化肽
|
TW201718627A
(zh)
|
2015-06-11 |
2017-06-01 |
梅茲製藥有限兩合公司 |
重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
|
TWI741992B
(zh)
|
2015-08-03 |
2021-10-11 |
美商百歐維拉提夫治療公司 |
因子ix融合蛋白以及其製備及使用方法
|
EA038329B1
(ru)
|
2015-08-28 |
2021-08-10 |
Амьюникс Фармасьютикалз, Инк. |
Химерный полипептидный комплекс и способы его получения и применения
|
US10040840B2
(en)
|
2015-10-02 |
2018-08-07 |
Silver Creek Pharmaceuticals, Inc. |
Bi-specific annexin A5/IGF-1 proteins and methods of use thereof to promote regeneration and survival of tissue
|
EP3373954A4
(en)
*
|
2015-11-10 |
2019-07-03 |
Proteothera, Inc. |
PROCESS FOR PREPARING AND CLEANING MATRIX-BINDING FUSION PROTEINS BY ION EXCHANGE CHROMATOGRAPHY
|
EP3919623A1
(en)
*
|
2015-12-22 |
2021-12-08 |
XL-protein GmbH |
Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences
|
AU2016381964B2
(en)
|
2015-12-30 |
2024-02-15 |
Kodiak Sciences Inc. |
Antibodies and conjugates thereof
|
US11389510B2
(en)
|
2016-01-08 |
2022-07-19 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release CNP agonists with low initial NPR-B activity
|
MX2018008061A
(es)
|
2016-01-08 |
2018-08-23 |
Ascendis Pharma Growth Disorders As |
Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
|
MY195190A
(en)
|
2016-01-08 |
2023-01-11 |
Ascendis Pharma Growth Disorders As |
Controlled-Release Cnp Agonists With Increased Nep Stability
|
AU2017205694B2
(en)
|
2016-01-08 |
2022-05-26 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release CNP agonists with low NPR-C binding
|
WO2017118707A1
(en)
|
2016-01-08 |
2017-07-13 |
Ascendis Pharma Growth Disorders A/S |
Controlled-release cnp agonists with reduced side-effects
|
US11413351B2
(en)
|
2016-01-08 |
2022-08-16 |
Ascendis Pharma Growth Disorders A/S |
CNP prodrugs with carrier attachment at the ring moiety
|
ES2929347T3
(es)
|
2016-01-20 |
2022-11-28 |
Merz Pharma Gmbh & Co Kgaa |
Nuevas neurotoxinas clostridiales recombinantes con aumento de la duración del efecto
|
PT3411478T
(pt)
|
2016-02-01 |
2022-09-13 |
Bioverativ Therapeutics Inc |
Genes do fator viii otimizados
|
KR20230015517A
(ko)
|
2016-03-01 |
2023-01-31 |
아센디스 파마 본 디지즈 에이/에스 |
Pth 프로드럭
|
US10676517B2
(en)
|
2016-03-10 |
2020-06-09 |
Medimmune Limited |
Glucagon and GLP-1 co-agonists for the treatment of obesity
|
CA3022751A1
(en)
*
|
2016-05-04 |
2017-11-09 |
Navigo Proteins Gmbh |
Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
|
CA3021644A1
(en)
|
2016-05-06 |
2017-11-09 |
Phasebio Pharmaceuticals, Inc. |
Elp fusion proteins for controlled and sustained release
|
AU2017295938C1
(en)
|
2016-07-13 |
2021-10-07 |
Ascendis Pharma A/S |
Conjugation method for carrier-linked prodrugs
|
JP7039574B2
(ja)
|
2016-09-29 |
2022-03-22 |
アセンディス ファーマ ボーン ディジージズ エー/エス |
放出制御pth化合物の漸増用量設定
|
IL265591B2
(en)
|
2016-09-29 |
2023-12-01 |
Ascendis Pharma Bone Diseases As |
Dosing regimen for a controlled-release PTH compound
|
MX2019003182A
(es)
|
2016-09-29 |
2019-08-05 |
Ascendis Pharma Bone Diseases As |
Compuestos de hormona paratiroidea con bajas relaciones pico - valle.
|
BR112019005351A2
(pt)
|
2016-09-29 |
2019-06-11 |
Ascendis Pharma Growth Disorders As |
terapia combinada com agonistas de cnp de liberação controlada
|
CN110520149A
(zh)
|
2016-12-02 |
2019-11-29 |
比奥维拉迪维治疗股份有限公司 |
诱导对凝血因子的免疫耐受性的方法
|
US20190381149A1
(en)
|
2016-12-02 |
2019-12-19 |
Bioverativ Therapeutics Inc. |
Methods of treating hemophilic arthropathy using chimeric clotting factors
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
MA47163A
(fr)
|
2016-12-16 |
2019-11-06 |
Biogen Ma Inc |
Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé
|
MX2019009063A
(es)
|
2017-01-31 |
2019-10-21 |
Bioverativ Therapeutics Inc |
Proteinas de fusion del factor ix y procedimientos de preparacion y utilizacion de las mismas.
|
CA3054068A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
PT3596116T
(pt)
|
2017-03-16 |
2023-12-04 |
Alpine Immune Sciences Inc |
Proteínas imunomoduladoras de pd-l1 variante e suas utilizações
|
AU2018235835A1
(en)
|
2017-03-16 |
2019-09-05 |
Alpine Immune Sciences, Inc. |
PD-L2 variant immunomodulatory proteins and uses thereof
|
CA3059938A1
(en)
|
2017-04-14 |
2018-10-18 |
Kodiak Sciences Inc. |
Complement factor d antagonist antibodies and conjugates thereof
|
JP7209637B2
(ja)
|
2017-04-21 |
2023-01-20 |
ヴォリューション イミュノ ファーマシューティカルズ エスエイ |
自己免疫性水疱症の治療のためのコバーシン
|
US11952601B2
(en)
|
2017-06-20 |
2024-04-09 |
Merz Pharma Gmbh & Co. Kgaa |
Recombinant botulinum toxin with increased duration of effect
|
US10174302B1
(en)
|
2017-06-21 |
2019-01-08 |
Xl-Protein Gmbh |
Modified L-asparaginase
|
WO2018234455A1
(en)
|
2017-06-21 |
2018-12-27 |
Xl-Protein Gmbh |
CONJUGATES OF PROTEIN MEDICINAL PRODUCTS AND PEPTIDES M / S
|
KR20200030065A
(ko)
|
2017-06-21 |
2020-03-19 |
재즈 파마슈티칼즈 아일랜드 리미티드 |
변형된 l-아스파라기나아제
|
EP3649143B1
(en)
|
2017-07-06 |
2022-08-31 |
Merz Pharma GmbH & Co. KGaA |
Novel recombinant botulinum neurotoxins with increased duration of effect
|
CN111247251A
(zh)
|
2017-08-09 |
2020-06-05 |
比奥维拉迪维治疗股份有限公司 |
核酸分子及其用途
|
TW201925223A
(zh)
|
2017-10-18 |
2019-07-01 |
美商艾爾潘免疫科學有限公司 |
變異型icos 配位體免疫調節蛋白及相關組合物及方法
|
ES2923152T3
(es)
*
|
2017-11-06 |
2022-09-23 |
Thena Biotech S R L |
Proteínas de fusión basadas en ferritina humana y péptidos escindibles por proteasas y su uso como vehículos quimioterapéuticos
|
EP3483619A1
(en)
*
|
2017-11-13 |
2019-05-15 |
Technische Universität München |
Automated noninvasive determining the sex of an embryo of and the fertility of a bird's egg
|
AU2019205273B2
(en)
|
2018-01-03 |
2024-04-04 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
BR112020015228A2
(pt)
|
2018-02-01 |
2020-12-29 |
Bioverativ Therapeutics Inc. |
Uso de vetores lentivirais que expressam fator viii
|
GB201804092D0
(en)
*
|
2018-03-14 |
2018-04-25 |
Imperial Innovations Ltd |
Methods and compositions
|
US11359000B2
(en)
|
2018-03-28 |
2022-06-14 |
Bristol-Myers Squibb Company |
Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
|
WO2019185706A1
(en)
|
2018-03-28 |
2019-10-03 |
Ascendis Pharma A/S |
Conjugates
|
JP2021519336A
(ja)
|
2018-03-28 |
2021-08-10 |
アセンディス ファーマ オンコロジー ディヴィジョン エー/エス |
Il−2コンジュゲート
|
TW202015723A
(zh)
|
2018-05-18 |
2020-05-01 |
美商百歐維拉提夫治療公司 |
治療a型血友病的方法
|
MX2020012179A
(es)
|
2018-05-18 |
2021-01-29 |
Ascendis Pharma Bone Diseases As |
Dosis inicial de conjugados de hormona paratiroidea (pth).
|
US20210363219A1
(en)
|
2018-06-15 |
2021-11-25 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
CA3104686A1
(en)
|
2018-07-03 |
2020-01-09 |
Bristol-Myers Squibb Company |
Fgf-21 formulations
|
SG11202101157VA
(en)
|
2018-08-09 |
2021-03-30 |
Bioverativ Therapeutics Inc |
Nucleic acid molecules and uses thereof for non-viral gene therapy
|
JP2022500389A
(ja)
|
2018-09-10 |
2022-01-04 |
ヴォリューション イミュノ ファーマシューティカルズ エスエイ |
リウマチ性疾患の治療に使用するためのコバーシン
|
EP4321530A2
(en)
|
2018-09-27 |
2024-02-14 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
CN111040021B
(zh)
*
|
2018-10-12 |
2023-06-02 |
浙江道尔生物科技有限公司 |
一种改善生物活性蛋白性质的载体蛋白
|
JP2022013959A
(ja)
*
|
2018-11-02 |
2022-01-19 |
味の素株式会社 |
融合タンパク質
|
CN111153965A
(zh)
*
|
2018-11-07 |
2020-05-15 |
浙江道尔生物科技有限公司 |
用于改善活性蛋白或多肽性能的人工重组蛋白及其应用
|
JP2022513626A
(ja)
|
2018-11-26 |
2022-02-09 |
ノバルティス アーゲー |
Lpl-gpihbp1融合ポリペプチド
|
CA3120868A1
(en)
|
2018-11-30 |
2020-06-04 |
Alpine Immune Sciences, Inc. |
Cd86 variant immunomodulatory proteins and uses thereof
|
TW202039855A
(zh)
|
2018-12-06 |
2020-11-01 |
美商百歐維拉提夫治療公司 |
表現因子ix之慢病毒載體的用途
|
EP3923905A1
(en)
|
2019-02-11 |
2021-12-22 |
Ascendis Pharma Bone Diseases A/S |
Liquid pharmaceutical formulations of pth conjugates
|
CA3129352A1
(en)
|
2019-02-11 |
2020-08-20 |
Ascendis Pharma Growth Disorders A/S |
Dry pharmaceutical formulations of cnp conjugates
|
US20220088147A1
(en)
|
2019-03-04 |
2022-03-24 |
Ascendis Pharma Endocrinology Division A/S |
Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
|
US20220323519A1
(en)
|
2019-04-17 |
2022-10-13 |
Codiak Biosciences, Inc. |
Compositions of exosomes and aav
|
GB201905810D0
(en)
|
2019-04-25 |
2019-06-05 |
Volution Immuno Pharmaceuticals Sa |
Method of treatment
|
US20220387608A1
(en)
|
2019-06-18 |
2022-12-08 |
Bayer Aktiengesellschaft |
Adrenomedullin-analogues for long-term stabilization and their use
|
WO2020254602A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma A/S |
Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds
|
CN114026080A
(zh)
|
2019-06-21 |
2022-02-08 |
阿森迪斯药物股份有限公司 |
含有提供π-电子对的杂芳族氮的化合物的缀合物
|
CA3143442A1
(en)
|
2019-06-21 |
2020-12-24 |
Ascendis Pharma A/S |
Conjugates of heteroaromatic nitrogen-comprising compounds
|
MX2022002337A
(es)
|
2019-08-27 |
2022-06-08 |
Tonix Pharma Ltd |
Polipéptidos de tff2 modificados.
|
CA3153803A1
(en)
|
2019-09-27 |
2021-04-01 |
Volution Immuno Pharmaceuticals Sa |
Method of treatment of hematopoietic stem cell transplant associated thrombotic microangiopathy (hsct-tma)
|
TW202126284A
(zh)
|
2019-09-30 |
2021-07-16 |
美商百歐維拉提夫治療公司 |
慢病毒載體配製物
|
AU2020364071A1
(en)
|
2019-10-10 |
2022-05-26 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
CN116925237A
(zh)
|
2019-12-31 |
2023-10-24 |
北京质肽生物医药科技有限公司 |
Glp-1和gdf15的融合蛋白以及其缀合物
|
MX2022007916A
(es)
|
2020-01-03 |
2022-07-21 |
Ascendis Pharma As |
Conjugados que experimentan rearreglos intramoleculares.
|
CN115322794A
(zh)
|
2020-01-11 |
2022-11-11 |
北京质肽生物医药科技有限公司 |
Glp-1和fgf21的融合蛋白的缀合物
|
IL294357A
(en)
|
2020-01-13 |
2022-08-01 |
Ascendis Pharma Bone Diseases As |
Treatment of hypothyroidism
|
TW202208414A
(zh)
|
2020-05-08 |
2022-03-01 |
美商艾爾潘免疫科學有限公司 |
April及baff抑制性免疫調節蛋白及其使用方法
|
BR112022022826A2
(pt)
|
2020-06-03 |
2022-12-13 |
Ascendis Pharma Oncology Div A/S |
Sequências de il-2 e usos das mesmas
|
EP4192508A1
(en)
|
2020-08-05 |
2023-06-14 |
Ascendis Pharma A/S |
Conjugates comprising reversible linkers and uses thereof
|
EP4192495A1
(en)
|
2020-08-07 |
2023-06-14 |
Bristol-Myers Squibb Company |
Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
|
IL300668A
(en)
|
2020-08-28 |
2023-04-01 |
Ascendis Pharma Oncology Div A/S |
Glycosylated IL-2 proteins and their uses
|
TW202228784A
(zh)
|
2020-09-23 |
2022-08-01 |
奧地利商艾柏力維亞生技有限公司 |
用以於一患者中螯合非預期的抗peg抗體的化合物
|
US20230364199A1
(en)
|
2020-09-28 |
2023-11-16 |
Ascendis Pharma Bone Diseases A/S |
Improvement of physical and mental well-being of patients with hypoparathyroidism
|
CA3193453A1
(en)
|
2020-09-30 |
2022-04-07 |
Beijing Ql Biopharmaceutical Co., Ltd. |
Polypeptide conjugates and methods of uses
|
WO2022115597A1
(en)
|
2020-11-25 |
2022-06-02 |
Bristol-Myers Squibb Company |
Methods of treating liver diseases
|
WO2022123459A1
(en)
|
2020-12-11 |
2022-06-16 |
Friedrich Miescher Institute For Biomedical Research |
Hdac6 binding proteins and their anti-viral use
|
EP4267628A1
(en)
|
2020-12-22 |
2023-11-01 |
XL-protein GmbH |
Antibodies specific for structurally disordered sequences
|
WO2022207798A1
(en)
|
2021-04-01 |
2022-10-06 |
Ascendis Pharma A/S |
Use of long-acting growth hormone for treating inflammation-induced diseases
|
TW202313974A
(zh)
|
2021-06-08 |
2023-04-01 |
瑞典商阿斯特捷利康公司 |
用於治療肝病之組合療法
|
WO2023028440A2
(en)
|
2021-08-23 |
2023-03-02 |
Bioverativ Therapeutics Inc. |
Baculovirus expression system
|
WO2023046732A1
(en)
|
2021-09-22 |
2023-03-30 |
Ascendis Pharma Bone Diseases A/S |
Long-acting pth compound treatments
|
WO2023110758A1
(en)
|
2021-12-13 |
2023-06-22 |
Ascendis Pharma Growth Disorders A/S |
Effective doses of cnp conjugates
|
WO2023227505A1
(en)
|
2022-05-23 |
2023-11-30 |
Ascendis Pharma Growth Disorders A/S |
Liquid pharmaceutical formulations of cnp compounds
|
EP4342460A1
(en)
|
2022-09-21 |
2024-03-27 |
NovoArc GmbH |
Lipid nanoparticle with nucleic acid cargo
|